Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

CSPC Pharmaceutical Group / Equity Capital Markets

<p>CSPC Pharma is raising USD250m today for general funding and future investment opportunities. In this insight, we will look at fundamentals of the company and score the deals in our ECM Framework. </p><h2>Placement specifics</h2><ul>
<li>Company Name: CSPC Pharmaceutical Group Ltd</li>
<li>Ticker: 1093 HK</li>
<li>Accelerated primary placement</li>
<li>Settlement is longer than normal, with stock settling on 20 Oct, 2017</li>
<li>Indicative deal price: 12.38-12.65</li>
<li>Last Traded Price: HKD13.24</li>
<li>Implied placing discount: 4-6%</li>
<li>Offer Size (m): USD249/HKD1,944</li>
<li>ADV…</li>
</ul>

CSPC Pharma is raising USD250m today for general funding and future investment opportunities. In this insight, we will look at fundamentals of the company and score the deals in our ECM Framework. Placement specifics
Company Name: CSPC Pharmaceutical Group Ltd
Ticker: 1093 HK
Accelerated primary placement
Settlement is longer than normal, with stock settling on 20 Oct, 2017
Indicative deal price: 12.38-12.65
Last Traded Price: HKD13.24
Implied placing discount: 4-6%
Offer Size (m): USD249/HKD1,944
ADV…


CSPC Pharma Placement: Visible Growth and Good Track Record